Source link : https://www.newshealth.biz/health-news/nirsevimab-effectiveness-against-severe-rsv-holds-up-in-real-world-study/
The monoclonal antibody nirsevimab (Beyfortus) protected young infants against hospitalization for respiratory syncytial virus (RSV), pediatric intensive care unit (PICU) admissions, and mechanical ventilation, according to the French prospective ENVIE study. In a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis (95% CI 73.4-89.2) in infants younger […]
Author : News Health
Publish date : 2024-07-10 21:00:00
Copyright for syndicated content belongs to the linked Source.
Categories